A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally
NCT05098938 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2020
Last updated 2025-09-02
Summary
Researchers are looking for a better way to treat people who have recurrent herpes labialis, also known as cold sores. This is a type of viral infection that causes redness and blisters on the mouth and lip and that recurs.
Herpes labialis is caused by a virus called the herpes simplex virus (HSV). The infection is spread when a person comes into direct contact with someone else who has the infection. Once a person becomes infected with HSV, the virus multiplies and spreads, which can cause redness and blistering on the mouth and lip. The blisters crust over and heal. Once healed, the virus is said to go into an "inactive" phase. This means the virus does not cause any symptoms, but still remains in the body. HSV can then become "active" again. This means causing cold sore lesions to reappear. HSV can become active in different ways. Some of these include when a person has a fever, comes into contact with strong sunlight or has a condition that lowers one's immune system It can also happen during a woman's menstrual cycle, also called a period.
In this study, the researchers want to gather additional data on acyclovir 50 mg tablet, an available treatment for herpes labialis. It is a buccal tablet that sticks to the gum inside the mouth and directly treats the infected area to help stop the HSV from multiplying and spreading.
In this study, the researchers want to compare the efficacy of acyclovir 50 mg buccal tablets versus placebo in the treatment of herpes labialis. A placebo is a treatment that looks like the study medicine but does not have any medicine in it. Study participants will include those who have had at least 4 episodes of herpes labialis within the past 12 months prior to joining the study. To compare the study treatments, the researchers will measure the "duration of episode" (DOE) for each participant. DOE is amount of time it takes for symptoms to disappear and for herpes labialis lesions to heal after taking the study treatment. A doctor will look at the participants' symptom scores and facial images to determine the DOE. Assessments will be done over a period of 14 days.
The participants in this study will apply either acyclovir 50mg buccal tablet or the placebo as a tablet to the upper gum 1 time.
There will be a 2 week treatment phase and a 12 month follow up phase. The participants in this study will not be required to visit the study site. Instead, the participants will have virtual meetings with the study doctors from their homes using the internet. During the treatment phase, there will be 2 meetings. Throughout the follow up phase, the doctors will call the participants 4 times. Each participant will be in the study for about 20 months.
During the treatment phase of the study, the participants will:
* take their blood pressure and pulse
* check their mouth health through a questionnaire
* take pictures of their face and herpes labialis symptoms During the whole study the participants will answer questions about how they are feeling, what medications they are taking, and what adverse events they are having.
The doctors will keep track of any adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.
Conditions
- Recurrent Herpes Labialis
Interventions
- DRUG
-
Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773
Oral (upper gum area), 50mg, 1 tablet.
- DRUG
-
Oral (upper gum area), 1 table.
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-11-23
- Primary Completion
- 2023-07-19
- Completion
- 2024-07-02
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis
NCT00297011 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Topical Antiviral Agents for Labial Cold Sores (Herpes Labialis)
NCT00467662 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of Acyclovir-penciclovir Cream Versus an Abreva in the Suppression of Herpes Simplex Virus Eruptions
NCT06558838 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis
NCT00361881 ·Status: COMPLETED ·Phase: PHASE3
-
Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients
NCT00735761 ·Status: COMPLETED ·Phase: PHASE3
-
Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes
NCT02871492 ·Status: COMPLETED ·Phase: PHASE2
-
Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis
NCT01257074 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis
NCT01971385 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 2, Muti-Center Study of Repeat Dosing of Squaric Acid Dibutyl Ester in Subjects With Herpes Labialis
NCT03521479 ·Status: TERMINATED ·Phase: PHASE2
-
Herpes Simplex Type 1 Suppression in Hepatitis C
NCT01580995 ·Status: COMPLETED ·Phase: PHASE2
-
An Exploratory Study to Investigate the Inflammatory Response During a Cold Sore Episode
NCT01653509 ·Status: COMPLETED ·Phase: PHASE1
-
Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections.
NCT04065971 ·Status: RECRUITING ·Phase: PHASE4
-
NB-001 Treatment of Recurrent Herpes Labialis
NCT01695187 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons
NCT00161434 ·Status: COMPLETED ·Phase: PHASE4
-
Valaciclovir to Prevent Transmission of Herpes Simplex Virus
NCT00001649 ·Status: COMPLETED ·Phase: PHASE3
-
A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation
NCT00723229 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Acyclovir in Combination With a Glucocorticosteroid on UV-Induced Herpes Labialis
NCT00736437 ·Status: COMPLETED ·Phase: PHASE2
-
Place Controlled Study to Treat Recurrent Herpes Labialis.
NCT00914745 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
NCT00076232 ·Status: COMPLETED ·Phase: PHASE3
-
Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
NCT00362297 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes
NCT06698575 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients
NCT00000953 ·Status: COMPLETED ·Phase: PHASE2
-
Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes
NCT01687595 ·Status: COMPLETED ·Phase: PHASE2
-
HSV-2 Shedding Resolution After Acyclovir Treatment
NCT00495573 ·Status: COMPLETED
-
Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection
NCT01915212 ·Status: COMPLETED ·Phase: PHASE1